An Eli Lilly executive said he expects the Centers for Medicare & Medicaid Services to back down from strict coverage limits on new Alzheimer’s drugs. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. (Reuters)
A change to a Colorado bill capping the cost of EpiPens would let drugmakers offer alternatives to the state program. House Bill 23-1002 would create a program allowing residents to access epinephrine for no more than $60 for a pack of two auto-injectors, starting in January. (The Denver Post)
‘Pharma Bro’ Martin Shkreli unveiled a medical chatbot called “Dr. Gupta” that can answer a wide range of medical questions and could one day become a “replacement for all health care information.” Shkreli, who was released from prison last year after spending seven years behind bars for securities fraud, revealed his new AI tool this week. (Gizmodo)
A federal bankruptcy judge halted roughly 40,000 lawsuits that allege Johnson & Johnson’s baby powder and other talc products caused cancer. Judge Michael Kaplan during a hearing in U.S. Bankruptcy Court in Trenton, New Jersey, put a temporary hold on the suits that will last through mid-June. (CNBC)
Activist Bluebell stepped up pressure for a Bayer breakup and supervisory board changes. Activist investor Bluebell Capital Partners is reportedly renewing a call for German agriculture and drug company Bayer to break up. (Seeking Alpha)
